Top

Published in:

01-07-2014 | Research Article

The expression and clinical significance of high mobility group nucleosome binding domain 5 in human osteosarcoma

Authors: Xuhui Zhou, Bo Yuan, Wen Yuan, Ce Wang, Rui Gao, Junyan Wang

Published in: Tumor Biology | Issue 7/2014

Abstract

The high mobility group nucleosome binding domain 5 (HMGN5) is a member of the high mobility group proteins family and highly expressed in multiple malignancies. Nevertheless, the role of HMGN5 in osteosarcoma remains unclear. This study aimed to investigate the expression and clinical significance of HMGN5 in human osteosarcoma, confirm the oncogenic role of HMGN5 and explore the mechanism by which HMGN5 contributes to invasion and metastasis. HMGN5 expression was detected in osteosarcoma tissues and corresponding adjacent non-cancerous tissues (ANCTs) from 52 patients by immunohistochemical (IHC) assay and the clinicopathologic characteristics of all patients were also recorded. Next, osteosarcoma cells were transfected by HMGN5 RNA interference and cell viability, apoptosis and invasion were detected by cell vitality test, flow cytometry and transwell assay, respectively. As a result, IHC assay showed strong immunized activity of HMGN5 in the nucleus in all osteosarcoma tissues compared with the ANCT (53.5 ± 4.3 % vs. 17.0 ± 3.9 %, P < 0.01). HMGN5 expression level was associated with pathologic staging and TNM staging. Knockdown of HMGN5 induced cell cycle arrest, inhibited invasion and increased sensitivity to doxorubicin–induced cell apoptosis in U2-OS and SaO2 cells. Western blot analysis demonstrated that there were increased expressions of cleaved caspase-3, cleaved PARP and decreased expressions of PCNA, PI3Kp85α, p-AKT, MMP-9, and cyclin B1 in U2-OS and SaO2 cells depleted of HMGN5. HMGN5 plays oncogenic role in osteosarcoma by promoting cell proliferation and invasion, and could be exploited as a target for therapy in osteosarcoma.

Huang J, Ni J, Liu K, Yu Y, Xie M, Kang R, et al. HMGB1 promotes drug resistance in osteosarcoma. Cancer Res. 2012;72(1):230–8. doi:10.1158/0008-5472.CAN-11-2001.CrossRefPubMed

Meyers PA, Schwartz CL, Krailo MD, Healey JH, Bernstein ML, Betcher D, et al. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival—a report from the Children's Oncology Group. J Clin Oncol. 2008;26(4):633–8. doi:10.1200/JCO.2008.14.0095.CrossRefPubMed

Gill M, McCarthy M, Murrells T, Silcocks P. Chemotherapy for the primary treatment of osteosarcoma: population effectiveness over 20 years. Lancet. 1988;1(8587):689–92.CrossRefPubMed

Bustin M, Reeves R. High-mobility-group chromosomal proteins: architectural components that facilitate chromatin function. Prog Nucleic Acid Res Mol Biol. 1996;54:35–100.CrossRefPubMed

Bustin M. Regulation of DNA-dependent activities by the functional motifs of the high-mobility-group chromosomal proteins. Mol Cell Biol. 1999;19(8):5237–46.PubMedCentralPubMed

Pritsker M, Ford NR, Jenq HT, Lemischka IR. Genomewide gain-of-function genetic screen identifies functionally active genes in mouse embryonic stem cells. Proc Natl Acad Sci U S A. 2006;103(18):6946–51. doi:10.1073/pnas.0509861103.PubMedCentralCrossRefPubMed

Huang C, Zhou LQ, Song G. Effect of nucleosomal binding protein 1 in androgen-independent prostatic carcinoma. Zhonghua Yi Xue Za Zhi. 2008;88(10):657–60.PubMed

Green J, Ikram M, Vyas J, Patel N, Proby CM, Ghali L, et al. Overexpression of the Axl tyrosine kinase receptor in cutaneous SCC-derived cell lines and tumours. Br J Cancer. 2006;94(10):1446–51. doi:10.1038/sj.bjc.6603135.PubMedCentralCrossRefPubMed

Tang WY, Newbold R, Mardilovich K, Jefferson W, Cheng RY, Medvedovic M, et al. Persistent hypomethylation in the promoter of nucleosomal binding protein 1 (Nsbp1) correlates with overexpression of Nsbp1 in mouse uteri neonatally exposed to diethylstilbestrol or genistein. Endocrinology. 2008;149(12):5922–31. doi:10.1210/en.2008-0682.PubMedCentralCrossRefPubMed

10.

Li DQ, Hou YF, Wu J, Chen Y, Lu JS, Di GH, et al. Gene expression profile analysis of an isogenic tumour metastasis model reveals a functional role for oncogene AF1Q in breast cancer metastasis. Eur J Cancer. 2006;42(18):3274–86. doi:10.1016/j.ejca.2006.07.008.CrossRefPubMed

11.

Wahafu W, He ZS, Zhang XY, Zhang CJ, Yao K, Hao H, et al. The nucleosome binding protein NSBP1 is highly expressed in human bladder cancer and promotes the proliferation and invasion of bladder cancer cells. Tumour Biol. 2011;32(5):931–9. doi:10.1007/s13277-011-0195-0.CrossRefPubMed

12.

Ji SQ, Yao L, Zhang XY, Li XS, Zhou LQ. Knockdown of the nucleosome binding protein 1 inhibits the growth and invasion of clear cell renal cell carcinoma cells in vitro and in vivo. J Exp Clin Cancer Res. 2012;31:22. doi:10.1186/1756-9966-31-22.PubMedCentralCrossRefPubMed

13.

Rochman M, Malicet C, Bustin M. HMGN5/NSBP1: a new member of the HMGN protein family that affects chromatin structure and function. Biochim Biophys Acta. 2010;1799(1–2):86–92. doi:10.1016/j.bbagrm.2009.09.012.PubMedCentralCrossRefPubMed

14.

Chiu CC, Lin CH, Fang K. Etoposide (VP-16) sensitizes p53-deficient human non-small cell lung cancer cells to caspase-7-mediated apoptosis. Apoptosis. 2005;10(3):643–50. doi:10.1007/s10495-005-1898-8.CrossRefPubMed

15.

Li B, Yang Y, Jiang S, Ni B, Chen K, Jiang L. Adenovirus-mediated overexpression of BMP-9 inhibits human osteosarcoma cell growth and migration through downregulation of the PI3K/AKT pathway. Int J Oncol. 2012;41(5):1809–19. doi:10.3892/ijo.2012.1617.CrossRefPubMed

16.

Evan GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer. Nature. 2001;411(6835):342–8. doi:10.1038/3507721335077213.CrossRefPubMed

17.

Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell. 1993;75(4):805–16.CrossRefPubMed

18.

Liu SY, Chen CL, Yang TT, Huang WC, Hsieh CY, Shen WJ, et al. Albumin prevents reactive oxygen species-induced mitochondrial damage, autophagy, and apoptosis during serum starvation. Apoptosis. 2012;17(11):1156–69. doi:10.1007/s10495-012-0758-6.CrossRefPubMed

19.

Yang YH, Chen K, Li B, Chen JW, Zheng XF, Wang YR, et al. Estradiol inhibits osteoblast apoptosis via promotion of autophagy through the ER–ERK–mTOR pathway. Apoptosis. 2013;18(11):1363–75. doi:10.1007/s10495-013-0867-x.CrossRefPubMed

20.

King LM, Francomano CA. Characterization of a human gene encoding nucleosomal binding protein NSBP1. Genomics. 2001;71(2):163–73. doi:10.1006/geno.2000.6443.CrossRefPubMed

21.

Hock R, Furusawa T, Ueda T, Bustin M. HMG chromosomal proteins in development and disease. Trends Cell Biol. 2007;17(2):72–9. doi:10.1016/j.tcb.2006.12.001.PubMedCentralCrossRefPubMed

22.

Nielsen-Preiss SM, Silva SR, Gillette JM. Role of PTEN and Akt in the regulation of growth and apoptosis in human osteoblastic cells. J Cell Biochem. 2003;90(5):964–75. doi:10.1002/jcb.10709.CrossRefPubMed

23.

Pines J, Hunter T. Human cyclins A and B1 are differentially located in the cell and undergo cell cycle-dependent nuclear transport. J Cell Biol. 1991;115(1):1–17.CrossRefPubMed

24.

Symonds H, Krall L, Remington L, Saenz-Robles M, Lowe S, Jacks T, et al. p53-dependent apoptosis suppresses tumor growth and progression in vivo. Cell. 1994;78(4):703–11.CrossRefPubMed

25.

Wittig JC, Bickels J, Priebat D, Jelinek J, Kellar-Graney K, Shmookler B, et al. Osteosarcoma: a multidisciplinary approach to diagnosis and treatment. Am Fam Physician. 2002;65(6):1123–32.PubMed

Title: The expression and clinical significance of high mobility group nucleosome binding domain 5 in human osteosarcoma
Authors: Xuhui Zhou
Bo Yuan
Wen Yuan
Ce Wang
Rui Gao
Junyan Wang
Publication date: 01-07-2014
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 7/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-014-1825-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 7/2014

Quantitation of rare circulating tumor cells by folate receptor α ligand-targeted PCR in bladder transitional cell carcinoma and its potential diagnostic significance

Relationships of FOXE1 and ATM genetic polymorphisms with papillary thyroid carcinoma risk: a meta-analysis

Association between IRS-1 Gly972Arg polymorphism and colorectal cancer risk

Increased expression of HSP27 inhibits invasion and metastasis in human esophageal squamous cell carcinoma

Expression of LATS1 contributes to good prognosis and can negatively regulate YAP oncoprotein in non-small-cell lung cancer

Stat3 inhibits Beclin 1 expression through recruitment of HDAC3 in nonsmall cell lung cancer cells

Keynote webinar | Spotlight on antibody–drug conjugates in cancer